1744-859X-5-S1-S133 1744-859X Poster presentation <p>Clinical status course and quality of life after the first 1 year of treatment: greek results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study</p> Touloumis Charalambos Drossinos Vangelis Kyrana Maria Ntzamaras Kostas Sventzouri Fotini Mavreas Venetsanos Novick Diego

Psychiatric Hospital of Attica "Dafni", Greece

Medical Department of Clinical Research, Pharmaserve-Lilly, Greece

Department of Psychiatry, University Hospital of Ioannina, Greece

Eli Lilly and Company, Greece

 Annals of General Psychiatry <p>International Society on Brain and Behaviour: 2nd International Congress on Brain and Behaviour</p> Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. <p>International Society on Brain and Behaviour: 2nd International Congress on Brain and Behaviour</p> Thessaloniki, Greece 17–20 November 2005 1744-859X 2006 5 Suppl 1 S133 10.1186/1744-859X-5-S1-S133 28 2 2006

Background

European SOHO is a prospective, observational study of antipsychotic treatment in 10 European countries.

Materials and methods

Clinical effectiveness and Qol were assessed using the Clinical Global Impression (CGI) scale and the EQVAS instrument, respectively. The results that follow have been calculated by analysing treatment outcomes of SOHO patients who, from baseline to 12 months of follow-up, had only received the same monotherapy antipsychotic treatment (completers).

Results

Olanzapine-treated patients had higher benefit in overall CGI improvements (mean; 95% CI) during the first 12 months, compared with risperidone (2.51, 1.16–5.44), but not with quetiapine (1.16, 0.17–7.5) and oral typicals (1.6, 0.24–10.8)- treated patients.

Olanzapine-treated patients had no significant differences in EQVAS improvements during the first 12 months compared with other treatments.

Discussion

During the first 12 months of treatment olanzapine appears to have superior efficacy advantages compared with risperidone, but not with quetiapine or typical antipsychotics on clinical grounds. There was no differentiation between olanzapine and other typical and atypical antipsychotics regarding EQVAS score changes.